Pharmacists are being placed at the centre of a national movement to destigmatise dandruff and normalise scalp health, as Key Pharmaceuticals and Alliance Pharma celebrate five years of partnership and growth for Nizoral, Australia’s leading anti-dandruff treatment brand.
While dandruff and seborrheic dermatitis affect around half of the global population, the issue remains underdiscussed compared to other skin conditions, such as acne or eczema. Despite its prevalence, dandruff is often viewed as merely cosmetic, a perception that can carry significant emotional and social implications for sufferers.
Recognising this gap, Key Pharmaceuticals and Alliance Pharma are championing pharmacists as key players in reframing scalp health as an essential part of overall wellness.
Five Years of Growth and Leadership
Since joining forces in 2020, the two companies have transformed Nizoral from a legacy treatment brand into a trusted, pharmacy-led scalp health solution. The partnership combines Alliance’s global consumer healthcare expertise with Key’s strong local market presence and pharmacy relationships.
Over the past five years, the collaboration has delivered:
Market leadership: Nizoral’s value market share has grown from 30.7 per cent in 2020 to 40.5 per cent in 2025, meaning four in every ten dollars spent on pharmacy anti-dandruff products in Australia go to Nizoral.
Double-digit growth: Pharmacy sales have more than doubled to over $14 million in 2025.
Nationwide expansion: Greater visibility and distribution across both independent and banner pharmacies.
Looking ahead, Alliance Pharma and Key Pharmaceuticals plan to deepen their investment in education, awareness, and innovation — positioning pharmacists as leaders in scalp wellness conversations.
Upcoming initiatives include:
Consumer and industry campaigns to normalise discussions around dandruff and scalp care.
Expanded pharmacist training and digital learning programs to build confidence in managing scalp health concerns.
Ongoing innovation to broaden product relevance and sustain long-term category growth.
“Pharmacists are often the first health professionals Australians consult when they notice a scalp issue,” said Meelian Hoh, CEO of Key Pharmaceuticals. “That puts them in a unique position to break the stigma, build consumer confidence, and ensure access to evidence-based treatments as part of everyday self-care.”
Michael Khor, Head of APAC at Alliance Pharma, added: “Great brands grow through great partnerships. With Key, we’ve built trust and delivered strong results — doubling sales and growing market share beyond 40%. The next phase is about going further: embedding scalp health within the broader wellness category, with pharmacists leading the way.”
